menu
    • menu
    [{"orgOrder":0,"company":"Rokote Laboratories","sponsor":"Exothera","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Partnership","leadProduct":"FINCoVac 2.0","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Rokote Laboratories","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Rokote Laboratories \/ Rokote Laboratories","highestDevelopmentStatusID":"4","companyTruncated":"Rokote Laboratories \/ Rokote Laboratories"},{"orgOrder":0,"company":"Rokote Laboratories","sponsor":"Cevec","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Licensing Agreement","leadProduct":"FINCoVac 2.1","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Rokote Laboratories","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Rokote Laboratories \/ ROKOTE Laboratories Finland","highestDevelopmentStatusID":"4","companyTruncated":"Rokote Laboratories \/ ROKOTE Laboratories Finland"}]

    Find Clinical Drug Pipeline Developments & Deals by Rokote Laboratories

    Menu

    Rokote Laboratories

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Rokote Laboratories

                            Finland arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Rokote Laboratories

                            Finland arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FINCoVac 2.1

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Recipient : Cevec

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Rokote Laboratories Licenses Cevec’s Cap® Ad Technology For Vaccine Manufacturing

                            Details : Under the agreement, CEVEC has granted ROKOTE a non-exclusive rights to use the CAP® Ad platform for the manufacturing of adeno-based vaccines (FINCoVac 2.1) for prophylactic and therapeutic use in infectious diseases such as COVID-19, influenza and RSV...

                            Brand Name : FINCoVac 2.1

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            September 20, 2022

                            Lead Product(s) : FINCoVac 2.1

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Recipient : Cevec

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Rokote Laboratories

                            Finland arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Rokote Laboratories

                            Finland arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FINCoVac 2.0

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Recipient : Exothera

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Rokote Laboratories Selects Exothera For GMP Manufacturing of Its Second-​generation Coronavirus Vaccine

                            Details : The FINCoVac vaccine is designed to program the nasopharyngeal cells to produce immune response-inducing modified SARS-CoV-2-viral spike protein. FINCoVac 2.0 represents an easy-to-administer booster for those who are already fully vaccinated with other ...

                            Brand Name : FINCoVac 2.0

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            April 01, 2022

                            Lead Product(s) : FINCoVac 2.0

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Recipient : Exothera

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth